Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Heron Therapeutics ( (HRTX) ) has shared an announcement.
On January 9, 2026, Heron Therapeutics reported preliminary, unaudited net revenue of approximately $40.5 million for the fourth quarter ended December 31, 2025, and about $154.9 million for full-year 2025, underscoring continued momentum across its acute care and oncology supportive care portfolio. Within Q4, CINVANTI remained the largest revenue contributor at roughly $22.9 million, while ZYNRELEF generated about $12.5 million and delivered the strongest quarter-over-quarter growth in the portfolio, rising around 35% versus the third quarter, with APONVIE and SUSTOL contributing approximately $3.8 million and $1.3 million, respectively; the solid top-line performance and particularly strong uptake of ZYNRELEF highlight progress in Heron’s acute care franchise and suggest strengthening commercial execution heading into the company’s final audited results.
The most recent analyst rating on (HRTX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Heron Therapeutics stock, see the HRTX Stock Forecast page.
Spark’s Take on HRTX Stock
According to Spark, TipRanks’ AI Analyst, HRTX is a Neutral.
Heron Therapeutics faces significant financial challenges, including high leverage and negative profitability, which weigh heavily on its overall stock score. While there are positive developments in product growth and strategic initiatives, these are offset by valuation concerns and technical indicators suggesting potential short-term volatility. The recent board appointment is a positive step but has a limited impact on the overall score.
To see Spark’s full report on HRTX stock, click here.
More about Heron Therapeutics
Heron Therapeutics, Inc., based in Cary, N.C., is a commercial-stage biotechnology company focused on developing and commercializing therapeutics that improve medical care for acute care and oncology patients. Its portfolio includes ZYNRELEF for postoperative pain, APONVIE and CINVANTI for prevention of chemotherapy- and surgery-related nausea and vomiting, and SUSTOL for chemotherapy-induced nausea and vomiting, leveraging proprietary drug delivery technologies to advance standards of care in these segments.
Average Trading Volume: 1,887,321
Technical Sentiment Signal: Sell
Current Market Cap: $231M
Learn more about HRTX stock on TipRanks’ Stock Analysis page.